# Inato

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inato

- Industry: Healthcare IT
- Headquarters: Paris, France
- Website: www.inato.com
- Total disclosed funding: $30M
- Latest round: Series A (Feb 13, 2023)
- Investors on record: 7

## About

Inato SAS is a clinical research technology company that utilizes artificial intelligence to improve patient identification and site selection, enhancing the efficiency of clinical trials for pharmaceutical sponsors.Founded in 2016 and headquartered in Paris, France, Inato SAS specializes in transforming clinical research through AI applications. The company was established by Kourosh Davarpanah, who leads as CEO. Inato has successfully closed 3 deals, with the most recent on February 13, 2023, during their SERIES A funding round, where they raised EUR 14.998 mn from investors including Cathay Capital and Obvious Ventures. The total amount raised to date is EUR 14.998 mn, valuing the company at EUR 87.881 mn.Inato specializes in transforming clinical research by leveraging artificial intelligence to enhance patient identification and site selection processes. Their core offerings include AI-driven patient pre-screening tools and a robust site selection platform, designed to streamline trial participant recruitment and improve operational efficiency. These tools facilitate the identification of suitable patients while significantly reducing the administrative burden on research sites. Inato serves a diverse client base that includes over 5,500 research sites and 25 pharmaceutical sponsors, emphasizing the importance of inclusive access to underrepresented patient populations. Their products are utilized across various geographical markets, with a focus on North America and Europe, addressing the specific needs of clinical research stakeholders in these regions.Inato generates revenue primarily through partnerships with pharmaceutical sponsors and research sites, utilizing a business-to-business (B2B) transaction model. This structure often involves subscription agreements or contractual partnerships, where sponsors pay for access to Inato's platforms and services. The company’s cornerstone services, notably the AI Patient Pre-Screening and AI Site Selection tools, are integral to these transactions, providing clients with the means to enhance trial efficiency and patient diversity. While specific pricing details for these services are not disclosed, the transactional framework suggests that sponsors engage Inato's offerings based on the value derived from improved recruitment and operational outcomes in their clinical trials.In March 2023, Inato SAS raised EUR 15 million in SERIES A funding led by returning investor Cathay Innovation, with participation from Obvious Ventures and new investors La Maison and Top Harvest Capital. This funding will be used to fuel product innovation, support international growth, and hire top talent. The company aims to expand its market presence, particularly in North America and Europe, enhancing its product offerings to better serve the evolving needs of clinical research.

## Funding rounds

- Series A, Feb 13, 2023, $16M — Cathay Capital, Obvious, La Maison Partners, Top Harvest Capital
- Series A, Dec 16, 2019, $13M — Cathay Capital, Serena, Obvious, Fly Ventures
- Seed, Feb 27, 2018, $1.6M — Serena, Kima Ventures, Fly Ventures

## Investors

- Serena (https://capitalatlas.ai/funds/serena) — Seed, Series A
- Kima Ventures (https://capitalatlas.ai/funds/kima-ventures) — Seed
- Fly Ventures (https://capitalatlas.ai/funds/fly-ventures) — Seed, Series A
- Cathay Capital — Series A
- Obvious (https://capitalatlas.ai/funds/obvious) — Series A
- La Maison Partners (https://capitalatlas.ai/funds/la-maison-partners) — Series A
- Top Harvest Capital (https://capitalatlas.ai/funds/top-harvest-capital) — Series A